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Objective: To evaluate the copper and zinc intake and serum levels in patients with juvenile rheumatoid arthritis (JRA),
considering the pauci and polyarticular types, the disease activity and duration, the number of inflamed joints and the use of
corticosteroids therapy.
Design: Cross-sectional study with control group.
Setting: Outpatients of the pediatric rheumatology public health clinic, of the Universidade Federal de Sa˜o Paulo=Escola Paulista
de Medicina, Brazil.
Subjects: Forty-one patients with JRA were evaluated and 23 patients’ brothers, as a control group.
Interventions: Copper and zinc intake evaluation by Food Register method. Copper and zinc serum levels by atomic absorption
spectrophotometry.
Results: The disease activity did not determine difference in copper (P¼0.624) and zinc (P¼ 0.705) intake, being predomi-
nantly below the Recommended Dietary Allowances. The serum copper in relation to control was statistically greater
(P¼ 0.018), showing that the number of inflamed joints is statistically significantly related with its variation (P¼ 0.001). The
serum zinc was not different either in relation to control (P¼0.940) or to the disease characteristics.
Conclusions: The evaluation of copper intake seems to be of fundamental importance. It may influence the efficiency of the
organic serum response. More research is needed to indicate, with security, adequate zinc intake.
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Introduction
Copper and zinc physiology is considered a matter of great
interest because of the possibility of being able to activate
many key enzymes in the cellular metabolism. Copper and
zinc are essential nutrients, and their daily intake is neces-
sary to prevent diseases (World Health Organization, 1996).
They are constituents of the superoxide-dismutase enzyme,
which performs intracellular antioxidant functions (Tuncer
et al, 1999). Copper is a constituent of ceruloplasmin, a
powerful extracellular antioxidant enzyme (Halliwell &
Gutteridge, 1990). The anti-inflammatory effects of copper
and zinc have been documented in animals (Milanino et al,
1988) and in humans (Milanino et al, 1993). On the other
hand, the acute or chronic inflammation induces metabo-
lism alterations of these minerals, determining alterations in
their serum and tissue levels (Soylak & Kirnap, 2001), as well
as triggering other nutritional impairments (Go´mez-Vaquero
et al, 2001). However, there are few studies about the copper
and zinc serum levels in juvenile rheumatoid arthritis ( JRA;
Makela et al, 1984; Honkanen et al, 1989; Bacon et al, 1990;
Haugen et al, 1992; Strano et al, 1995).
Therefore, we proposed to evaluate the copper and zinc
intake and serum levels in JRA patients, considering pauci
and polyarticular types; the disease activity and duration; the
number of inflamed joints and the use of corticosteroid
therapy.
Methods
Forty-one outpatients, 21 females, with mean age of 11.3 y
(range 3.3 – 17.8 y), of the Pediatric Rheumatology public
health clinic, of the Universidade Federal de Sa˜o Paulo,
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Escola Paulista de Medicina, Sa˜o Paulo, SP, Brazil, with JRA
were evaluated by a pediatric rheumatologist. The diagnosis
of JRA was based on the American College of Rheumatology
criteria (Brewer et al, 1977). Twenty-one patients presented
active disease, eight of the pauciarticular type and 13 of the
polyarticular type. Among the patients who did not present
active disease, 11 were of the pauciarticular and nine of the
polyarticular type.
The disease was considered active when there was at least
one active joint and changes in the erythrocyte sedimenta-
tion rate (ESR). The disease duration was calculated by the
relation between the time of the disease and the age of
the patient, in years. The number of inflamed joints (range
1 – 12) included the active pauci and polyarticular types,
totalling 21 patients. Corticosteroid therapy consisted of
prednisone administration, with doses in the range
4 – 12.5 mg=day at the pediatric rheumatologist’s criterion.
Patients with and without the present use of this treatment
were considered.
The control group was used for comparison of the Cu
and Zn serum levels and constituted 23 patients’ brothers,
13 female, with mean age of 9.9 y (range 4.7 – 17.2 y). The
inclusion criterion was the absence of acute or chronic
disease.
Consent was obtained in writing from parents, and the
Ethics Committee in Research of the Universidade Federal de
Sa˜o Paulo=Hospital Sa˜o Paulo approved the study.
Dietary evaluation
A four-consecutive-days food register (Karkek, 1987) method
was used, including one weekend. The copper and zinc
intake was calculated using the validated and standardized
Virtual Nutri-USP (Philippi et al, 1996) software.
The calculated dietary intake was compared with the
Recommended Dietary Allowances (RDA; National Research
Council, 1989).
Biochemical analysis
Blood samples were collected with patients fasting, between
8:00 and 9:00 a.m. The serum samples were kept at 718C
until assay. The serum samples were diluted with distilled
and deionized water from the Milli-Q-Plus System (Millipore
Corp.) in a 1:10 proportion (Whitehouse et al, 1982), and the
copper and zinc concentrations were determined by atomic
absorption spectrophotometry (Perkin-Elmer, model 5.100),
under the following conditions: wavelength 324.8 nm (Cu)
and 213.9 nm (Zn); slit 0.7 nm; air acetylene oxidant flame;
energy 71 (Cu) and 65 (Zn); duplicate reading with integra-
tion time of 2 s. Stock standard solutions of 1000 mg metal=l
(Perkin-Elmer, PEN 4300183 for Cu and PEN 9300178 for Zn)
were diluted with glycerol at 10% (Cu) and glycerol at 5%
(Zn), resulting in working standard solutions containing 0.1,
0.3, 0.5, 1.0 and 2.0 mg Cu or Zn=l. Accuracy was monitored
by comparison with the commercial Quality Control
Standard 21 (Perkin-Elmer, PEN 9300281) for both elements.
Results are expressed as mg Cu or Zn=dl.
All chemicals used were of analytical grade. Acid-washed
glassware was used throughout the study.
Statistical analysis
Student’s t-test for independent samples (Bussab & Morentin,
1987) was used for comparison of means between the eva-
luated groups. Pearson’s linear correlation coefficient (Bussab
& Morentin, 1987) was used for the quantification between
the observed numerical variables. Covariance analysis (Neter
et al, 1996) was used to compare the serum levels, controlled
for age. Multiple linear regression (Neter et al, 1996) was used
to verify the significance of the disease characteristics in the
copper and zinc serum levels. An alpha confidence level of
5% was adopted. The results are expressed as means and
standard deviations.
Results
Dietary evaluation
No intake differences were observed between the control and
JRA groups, respectively 1.290.70 and 1.210.60 for
copper (P¼0.644) and 8.123.30 and 8.193.18 for zinc
(P¼0.938). In both groups the mean copper and zinc intakes
were below the recommendation.
Daily mean intake of zinc (Table 1) did not show statistical
differences in patients with and without disease activity
(P¼0.705), not reaching the RDA recommendation in any
of the groups. Regarding copper, the mean intake also did
not show significant differences between the compared
groups (P¼ 0.624). Only 13 patients reached the safe
and adequate range of the recommended copper intake,
with a mean intake of 1.740.76 mg, which was statisti-
cally higher than the mean of the other 28 patients,
0.970.31 mg (P¼0.003).
Also, there was no statistical difference between male and
female patients with disease activity (P¼0.774 for copper
and P¼ 0.667 for zinc) and without disease activity
(P¼0.656 for copper and P¼ 0.930 for zinc; Table 2).
Table 1 Daily copper and zinc intake, determined by a 4 day food
register in JRA patients with and without disease activity
JRA
Activity
(n¼ 21)
No Activity
(n¼20) RDAa P
Copper (mg) 1.150.57 1.24 0.64 b 0.624
(0.6 – 3.2) (0.6 – 3.2) —
Zinc (mg) 8.423.7 8.04 2.5 10 – 15 0.705
(1.1 – 16.3) (3.1 – 12.9)
a
RDA, recommended dietary allowances.
b
4 – 6 y ¼1.0 – 1.5 mg Cu; 7 – 10 y ¼ 1.0 – 2.0 mg Cu;11 y ¼1.5 – 2.5 mg Cu.
P, descriptive level of Student’s t-test.
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Biochemical evaluation
As the JRA and control groups were not similar in relation to
gender distribution, the serum copper and zinc means were first
compared according to this variable, in each group (Table 3). In
the JRA patients group, there were no significant differences
in sex related to copper (P¼0.067) and zinc (P¼0.091) serum
levels. The same was observed in the control group subjects
for copper (P¼0.927), as well as for zinc (P¼0.298).
When the copper and zinc serum levels were compared by
sex between JRA and control groups (Table 4), only the JRA
group of males showed higher copper levels than the control
males (P¼0.004).
The comparison between the JRA and the control groups,
controlled for age, showed higher serum copper levels in the
JRA group (P¼0.018) and without statistical significant
difference for the zinc level (P¼0.940; Table 5).
When copper and zinc levels were compared considering
separately the disease activity, the pauci and polyarticular
types, the use of corticosteroid, the disease duration
and the number of inflamed joints (Table 6), it was verified
that only the disease activity and the number of inflamed
joints have showed statistical significance with copper
levels, presenting descriptive levels of 0.012 and 0.001,
respectively.
Table 2 Daily copper and zinc intake in male and female JRA patients with and without disease activity
JRA
Activity No activity
Male (n¼10) Female (n¼ 11) Male (n¼ 10) Female (n¼ 10)
Copper (mg) 1.190.29 1.120.76 1.31 0.73 1.18 0.59
(0.9 – 1.9) (0.3 – 3.2) (0.7 – 3.2) (0.6 – 1.4)
P¼ 0.774 P¼0.656
Zinc (mg) 8.704.83 7.982.71 8.10 2.19 7.99 2.90
(1.1 – 16.3) (3.7 – 12.6) (5.2 – 12.6) (3.1 – 12.9)
P¼ 0.667 P¼0.930
P, descriptive level of Student’s t-test.
Table 3 Serum copper and zinc comparison between gender of the JRA and control groups
JRA Control
Male (n¼ 20) Female (n¼21) Male (n¼10) Female (n¼ 13)
Copper (mg=dl) 154.0 35.7 133.533.5 125.513.8 126.5 33.0
(105 – 225) (90 – 235) (110 – 150) (80 – 190)
P¼0.067 P¼ 0.927
Zinc (mg=dl) 89.7 17.5 97.610.2 90.012.0 95.010.4
(65 – 125) (85 – 115) (70 – 110) (80 – 110)
P¼0.091 P¼ 0.298
P, descriptive level of Student’s t-test.
Table 4 Serum copper and zinc comparison between JRA and control groups according to gender
Male Female
JRA (n¼ 20) Control (n¼10) JRA (n¼ 21) Control (n¼13)
Copper (mg=dl) 154.0 35.7 125.5 13.8 133.5 33.5 126.5 33.0
(105 – 225) (110 – 150) (90 – 235) (80 – 190)
P¼ 0.004 P¼ 0.555
Zinc (mg=dl) 89.7 17.5 90.0 12.0 97.6 10.2 95.0 10.4
(65 – 125) (70 – 110) (70 – 110) (80 – 110)
P¼ 0.968 P¼ 0.476
P, descriptive level of Student’s t-test.
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The study of the combined relation between the level of
serum copper and the variables activity, type and disease
duration, use of corticosteroid and the number of inflamed
joints, from the multiple linear regression (Table 7), showed
that only the number of inflamed joints varies statistically
significantly with serum copper level (P¼0.001).
Discussion
Copper and zinc intake
It seems that JRA characteristics do not determine significant
differences in copper and zinc intake. Our results (Table 1)
confirm previous work (Bacon et al, 1990), and the type of
disease (pauci=poly=systemic) reported by other authors
(Bacon et al, 1990; Haugen et al, 1992). Nevertheless, the
majority of individuals of the control group and of the JRA
patients, with and without disease activity, did not reach the
RDA recommendation for both elements. Intakes below the
recommendation for healthy children are reported in many
regions, such as the USA (Hambidge et al, 1985), UK (World
Health Organization, 1996), Canada (Gibson et al, 1989),
Papua-New Guinea (Ross et al, 1986) and Brazil (Shrimpton,
1984). The nutrient intake recommendations are intended
for healthy people and any type of disease may change the
specific nutrient needs. However, JRA subjects as well as
healthy children presented lower than recommended
intakes of copper and zinc. However, for patients, this may
signify a greater deficit, as there may be an increase in
the requirements for those nutrients caused by the inflam-
matory process (Haugen et al, 1992) and by the specific
functions that copper and zinc have in inflammatory
diseases (Rosenstein & Caldwell, 1999).
Serum copper
As there was no statistical difference in the serum copper and
zinc levels between sex (Table 3), the male and female
subjects of the JRA and control groups were considered
together.
Our results regarding the increased serum copper level in
the JRA group in relation to the control group, controlled for
age (Table 5), are consistent with previous studies (Bacon
et al, 1990; Haugen et al, 1992; Strano et al, 1995). Ninety
percent of the serum copper is incorporated to the cerulo-
plasmin (Rosenstein & Caldwell, 1999), which is one of the
main extracellular antioxidants (Kiziltunc et al, 1998). There-
fore, the increase of serum copper may be due to the increase
of the ceruloplasmin, which is an acute phase protein
(Conforti et al, 1983), whose role in adjuvant arthritis is to
neutralize free oxygen radicals, mainly anion superoxide
(Zoli et al, 1998) in an attempt to stop the process of turning
chronic.
The deficient copper intake, observed in our patients,
which may lead to reduced intracellular copper and thus to
reduced defense against free radicals (Haugen et al, 1992),
probably did not damage the acute phase response to the
inflammatory process. This probably occurred because the
low copper intake was not enough to deplete the hepatic
reserves (Honkanen et al, 1991b), thus not impeding the
adequate synthesis of ceruloplasmin. There are two possible
explanations for this hypothesis. First, copper used to
increase ceruloplasmin synthesis could derive from changes
in the balance between intestinal absorption and excretion
of copper. Second, copper could come from other areas of
Table 5 Serum copper and zinc of subjects in JRA and control
groups, controlled for age
JRA
(n¼41)
Control
(n¼23) P
Copper (mg=dl) 143.5 35.7 126.025.9 P¼0.018
(90 – 235) (80 – 190)
Zinc (mg=dl) 93.7 14.6 92.611.3 P¼0.940
(65 – 125) (70 – 110)
P, descriptive level of Student’s t-test.
Table 6 Serum copper and zinc of patients with JRA, according
to the activity and type of disease, use of corticosteroid, disease
duration and number of inflamed joints
Copper (mg=dl) Zinc (mg=dl)
Activity
a
Activity (n¼21) 156.9 39.6 92.116.6
No activity (n¼20) 129.5 25.1 95.512.3
P¼ 0.012* P¼0.469
Type
a
Pauciarticular (n¼19) 136.8 37.6 94.410.5
Polyarticular (n¼22) 149.3 33.8 93.117.6
P¼ 0.270 P¼0.774
Corticosteroid therapya,b
Yes (n¼8) 163.1 36.7 89.321.1
No (n¼ 5) 159.0 26.3 88.0 15.2
P¼ 0.832 P¼0.902
Duration of disease
c
(n¼41)
Coefficient 70.011 0.214
P 0.946 0.178
Number of inflamed joints
c
(n¼ 21)
Coefficient 0.494 70.297
P 0.001* 0.059
a
Student’s t-test for independent samples.
b
Pearson’s linear correlation coefficient.
cPolyarticular type patients.
*Significant difference.
Table 7 Multiple linear regression of the relation between serum
copper level and the studied variablesa
Coefficients
Standard
error P
Constant 129.774 6.259 <0.001
Number of inflamed joints 5.038 1.419 0.001
Dependent variable, serum copper.
a
Variables: activity, type, disease duration, corticosteroid therapy and number
of inflamed joints.
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the organism, such as the kidneys and the red cells
(Conforti et al, 1983).
It is known that the cerulosplamin correlates with JRA
(Harvey et al, 1987) and rheumatoid arthritis (RA; Kiziltunc
et al, 1998) activity, explaining the result of the significantly
higher serum copper during the disease activity (Table 6).
The mean serum copper of patients without disease activity,
129.5 mg=dl, is within the normal serum values mentioned in
the literature (World Health Organization, 1996) and normal
value is expected in periods with no disease activity
(Milanino et al, 1985).
Serum copper did not show statistical difference between
the pauci and polyarticular types (Table 6), nevertheless, the
latter was greater than that of the control; P¼0.013 (not
shown). These results agree with those of Bacon et al (1990)
when comparing polyarticular patients with healthy chil-
dren. When the comparison is between the pauci and poly-
articular types, our results are not in accordance with those
of Haugen et al (1992). However, this difference may be due
to the fact that, in the study of those authors, only two
patients were using corticosteroids. If we consider that the
mineral bone density is diminished in the polyarticular type,
with and without the disease activity (Cassidy & Petty, 1995),
we can raise the hypothesis of Cu mobilization from bone:
once in the tissue, the mineral is probably found adsorbed to
the crystals (Hila´rio et al, 1991). This could also help to
explain the increased serum copper levels in JRA, particularly
in the polyarticular type.
The polyarticular group, as expected, presented serum
copper levels above normal values, although without statis-
tical difference due to the treatment with corticosteroids
(Table 6). Several authors have reported diminished levels
of copper during this treatment (Scudder et al, 1978a; Brown
et al, 1979). The decrease of serum copper could be due to the
use of corticosteroids, explaining the similar copper levels
found in patients not using corticosteroid therapy. However,
these results were obtained from a small number of observa-
tions, which could not represent reality, prohibiting further
discussions.
The disease duration did not show correlation with the
serum copper levels, even when the disease duration was
considered related to the age of the patient, as in this study
(Table 6), or when the duration of arthritis over 1 y was
considered (Honkanen et al, 1989), or the mean of 8.6 y
(Balogh et al, 1980).
The number of inflamed joints, besides correlating posi-
tively with serum copper level (Table 6), was the only disease
characteristic that showed statistical significance on the
variation of this level (Table 7). A total of 65 inflamed
joints in 12 male patients and a total of 47 in nine female
patients were observed. It was also observed that the mean
serum copper was not different between JRA and control
female subjects, while the mean serum copper of JRA males
was significantly higher than the mean of control males
(Table 4). Considering these results, the group of JRA male
alone could account for the difference of serum copper
between JRA and control groups, and this fact is probably
due to the higher number of inflamed joints observed in this
group. In the RA subjects, increased levels of serum copper
are accompanied by high levels of copper in the synovial
fluid (Biemond et al, 1984), possibly meaning acceleration of
the lgG aggregates formation (Gerber, 1974) that occur in the
synovial fluid of these patients (Winchester et al, 1970),
resulting in local articular ceruloplasmin protection against
oxidative damage (Scudder et al, 1978b; Kiziltunc et al, 1998).
Another possibility is that it may signify tissue damage by
the stability reduction of cellular membrane (Chvapil et al,
1972). This damage could occur due to the lack of capacity of
the tissues to use the extra copper because of the high
ceruloplasmin blood level or due to blocked copper recep-
tors. In this way, there is a situation in which tissues are
actually deficient in copper, a situation that is known to
cause defects in the structural stabilization of fibrous pro-
teins of the connective tissues and also lead to the dimin-
ished tensile strength of elastin and collagen (Hannson et al,
1975). For some authors, the increased serum copper in JRA
reflects the antioxidant activity, with possible protective
effects, especially in the presence of tissue damage or
destruction (Al-Timimi and Dormandy, 1977; Kiziltunc et al,
1998); this increase may signify an important component of
the systemic inflammatory response (Scudder et al, 1978a).
Serum zinc
The serum zinc study of the JRA group did not show
statistically significant difference, either in relation to the
control group (Table 5), or in relation to the disease char-
acteristics (Table 6), the serum level always being within the
range of normal values, 80 – 110 mg=dl, mentioned in the
literature (World Health Organization, 1996).
The unchanged serum zinc level under inflammatory
conditions is in accordance with the results of Aaseth et al
(1978) and of Matarran-Perez et al (1989). Nonetheless,
increased (Hannson et al, 1975) or decreased (Moretti et al,
1988; Tuncer et al, 1999; Soylak & Kirnap, 2001) serum levels
have also been observed, possibly due to the differences in
the studied patients, in the established treatment and in the
chosen fluids for the analysis of that element.
During inflammatory processes, zinc increase seems to
occur in the liver and also in the injured tissue, such as
synovial fluid of arthritic patients. As zinc is a cofactor for
the protein and nucleic acid synthesis, it is conceivable that
a portion of the accumulated zinc in the liver is involved in
the increased synthesis of acute phase proteins (Powanda et al,
1973). The interleukin-1, produced by stimulated macro-
phages, increases metallothionein-mediated hepatic uptake
(Honkanen et al, 1991a). The increased metallothionein
synthesis is necessary for the protein synthesis of the acute
phase (Oliva et al, 1987). In RA, decreased absorption and
hepatic accumulation were described, after a zinc tolerance
test (Naveh et al, 1997).
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Some results in the literature may explain normal or
decreased zinc levels, during inflammation. Thus, the sig-
nificant correlation between serum decrease and hepatocyte
increase may signify that this increase occurs at serum
depletion cost (Oliva et al, 1987; Zoli et al, 1998). Serum
albumin, which is an important Zn-carrier, is decreased
during inflammation, and presents positive correlation
with the reduced zinc levels (Milanino et al, 1993; Maes et al,
1997). Therefore, zinc absorption and distribution seems
to be disturbed in JRA (Honkanen et al, 1989), implying
that its serum level is probably, one of the nonspecific
features of inflammation (Balogh et al, 1980; Honkanen
et al, 1991a).
Corticosteroid treatment did not determine alteration in
the serum zinc (Table 6). Several results confirm that the
use of these drugs does not significantly influence serum
value of this mineral (Peretz et al, 1989; Milanino et al,
1993). It is known that corticosteroids increase zinc
transport to the membranes (Chvapil, 1976), as well as
to urine (Ellul-Micallef et al, 1976), zinc being, possibly, a
mediator of the membrane-stabilizing effect of the steroids
(Chvapil, 1976).
Conclusions
Considering the important role of the serum copper increase
in inflammatory response, the evaluation and orientation of
copper intake seems to us of fundamental importance, as
this may have influence in the organic serum response
efficiency.
In relation to zinc, more research is required to determine,
with security, adequate zinc intake.
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